Please login to the form below

Not currently logged in
Email:
Password:

InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients

Coronavirus new

A phase 3 study showed that the antibody reduced the all-cause mortality rate after 28 days

Amylyx’s Relyvrio receives FDA approval for ALS treatment

Relyvrio was shown to significantly slow physical decline in people living with ALS

Cancer Research UK scientists announce ‘breakthrough’ in understanding of metastasis

Cancer Research UK logoThe team found that cancer cells ‘exploit’ the body’s tissue repair process to spread cells

Sanofi and Regeneron’s Dupixent approved by FDA for prurigo nodularis

SanofiThe two phase 3 trials showed a meaningful reduction in itching

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

ShionogiEnsitrelvir reduced the time taken to resolve five key symptoms

Biogen and Eisai’s lecanemab shows promise in confirmatory Alzheimer’s study

BiogenResults from the phase 3 trial showed reduction in clinical decline

Genentech and ArsenalBio join to identify successful T-cell oncology therapies

GenentechWhile CAR-T therapy has shown promise in blood cancers, solid tumours present additional challenges

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

AZ NEWTezspire demonstrated reduced annualised rate of asthma exacerbations

Pfizer and BioNTech seek FDA authorisation for COVID-19 booster for children

Pfizer NY headquartersAn application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group

clusterAdopting a creative IP approach towards biotech clusters

Why big pharma paradigm needs to change

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....